JE
Therapeutic Areas
CSL Seqirus Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Next-Gen / Universal Flu Vaccines | Influenza | Research / Early Clinical |
| MF59-Adjuvanted Seasonal Vaccines | Seasonal Influenza | Marketed |
| Flucelvax Quadrivalent (cell-based) | Seasonal Influenza | Marketed |
| Flublok Quadrivalent (recombinant) | Seasonal Influenza | Marketed |
| Pandemic Preparedness Vaccines | Pandemic Influenza (e.g., H5N1) | Clinical Development |
| Adjuvanted Cell-Based COVID-19 Vaccine | COVID-19 | Marketed |